news
New data for Eisai’s eribulin presented at SABCS
11 December 2015 | By Victoria White
New data supports the previously shown ability of Eisai’s Halaven (eribulin) to reverse epithelial-to-mesenchymal transition...
List view / Grid view
Eisai
news
Eisai presents new data for perampanel at AES 2015
8 December 2015 | By Victoria White
New data, presented at AES 2015, show that Eisai's Fycompa (perampanel) treatment reduces primary and secondary generalised tonic clonic seizures and is well tolerated versus placebo...
news
Real world data for eslicarbazepine acetate presented at AES
7 December 2015 | By Victoria White
The data shows that a good proportion of people with partial-onset seizures, who have not responded when treated with carbamazepine, may respond to eslicarbazepine acetate...
news
Lenvatinib improves progression-free survival in renal cell carcinoma study
16 October 2015 | By Victoria White
Phase II results show lenvatinib, when used in combination with everolimus, demonstrates significantly improved PFS versus everolimus alone in people with metastatic renal cell carcinoma...
news
Data on Eisai’s eribulin and lenvatinib presented at DGHO
13 October 2015 | By Victoria White
Five abstracts have highlighted the use of Eisai’s eribulin and lenvatinib in rare cancers at the German Association of Hematology and Oncology Meeting...
news
Phase III data confirms efficacy of perampanel and rufinamide
9 September 2015 | By Victoria White
Data presented at the International Epilepsy Congress in Istanbul show Eisai’s perampanel may significantly reduce seizure frequency, both in patients with primary generalised tonic-clonic (PGTC) seizures and partial epilepsy...
news
Phase III study data for Fycompa in PGTC seizures published
24 August 2015 | By Victoria White
Phase III study results for Eisai’s Fycompa® (perampanel) in primary generalised tonic-clonic (PGTC) seizures have been published for the first time...
news
Eisai and Halozyme to investigate Halaven and PEGPH20 in metastatic breast cancer
31 July 2015 | By Victoria White
Eisai and Halozyme are to collaborate to evaluate Halaven in combination with PEGPH20 in first line HER2-negative metastatic breast cancer...
news
Eisai submits regulatory applications for eribulin in the US, EU and Japan
31 July 2015 | By Victoria White
Eisai has submitted regulatory applications in the US, EU and Japan for eribulin for the treatment of patients with inoperable soft tissue sarcoma (STS)...
news
Eisai’s Lenvima receives Breakthrough Therapy designation for renal cell carcinoma
29 July 2015 | By Victoria White
Eisai has received a Breakthrough Therapy designation for Lenvima for the potential indication of advanced and/or metastatic renal cell carcinoma...
news
First-in-class epilepsy treatment Fycompa launches in the UK
8 July 2015 | By Victoria White
Eisai’s Fycompa (perampanel), a once-daily epilepsy treatment that inhibits AMPA receptors, launches in the United Kingdom today...
news
Epilespy treatment perampanel receives marketing authorisation for primary generalised tonic-clonic seizures
25 June 2015 | By Victoria White
The EC has granted marketing authorisation approval for perampanel for primary generalised tonic-clonic (PGTC) seizures in patients with epilepsy...
news
Lenvima launches in the UK as a treatment for people with advanced thyroid cancer
9 June 2015 | By Victoria White
Lenvima launches in the UK today as a treatment option for people with radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC)...
news
EC approves anticancer agent Lenvima for treatment of advanced thyroid cancer
1 June 2015 | By Victoria White
The EC has approved Lenvima in the treatment of adult patients with progressive, locally advanced or metastatic differentiated thyroid carcinoma...
news
Eisai receives positive CHMP opinion on indication expansion for antiepileptic agent Fycompa as adjunctive treatment of PGTC seizures
27 May 2015 | By Victoria White
Eisai has received a positive opinion from the EMA’s CHMP for the use of Fycompa for the adjunctive treatment of PGTC seizures...
